{"id":499973,"date":"2021-06-02T08:23:47","date_gmt":"2021-06-02T12:23:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\/"},"modified":"2021-06-02T08:23:47","modified_gmt":"2021-06-02T12:23:47","slug":"i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\/","title":{"rendered":"I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SHANGHAI<\/span> and GAITHERSBURG, Md.<\/span>, June 2, 2021<\/span> \/PRNewswire\/ — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors on Monday, June 7<\/span> at 8:00 a.m. ET<\/span> to provide an in-depth clinical data analysis of its U.S. phase 1 study of uliledlimab in combination with atezolizumab (TECENTRIQ\u00ae) in patients with advanced cancers.<\/p>\n

\n

\n
\n \"I-MAB
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n I-Mab Conference Call Information<\/b>\n <\/p>\n

Investors and analysts are invited to join the conference call on June 7<\/span> at 8:00 a.m. ET<\/span> via Zoom:<\/p>\n

Meeting URL:\u00a0 https:\/\/zoom.us\/j\/99293081819?pwd=aHJjQ0o4Uk9kUEtzeHI1dngzUGREUT09<\/a>
Meeting ID:\u00a0\u00a0\u00a0\u00a0 992 9308 1819
Password:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 942873<\/p>\n

\n About Uliledlimab (TJD5) <\/b>\n <\/p>\n

Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine.\u00a0 Adenosine in turn binds to adenosine receptors on relevant immune cells and inhibits anti-tumor immune responses in tumor microenvironment.\u00a0 Uliledlimab is expected to offer clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Uliledlimab is effective in anti-tumor activities through a unique intra-dimer binding, leading to differentiated and favorable functional properties as evident in preclinical studies. <\/p>\n

\n About I-Mab<\/b>\n <\/p>\n

I-Mab (Nasdaq: IMAB) is an innovation-driven global biotech company focusing on discovery, development and soon commercialization of novel and highly differentiated biologics in immuno-oncology therapeutic area. The Company’s mission is to bring transformational medicines to patients around the world through drug innovation. I-Mab’s globally competitive pipeline of more than 15 clinical and pre-clinical stage drug candidates is driven by its internal R&D capability and global licensing partnerships, based on the Company’s unique Fast-to-Proof-of-Concept and Fast-to-Market pipeline development strategies. The Company is now rapidly progressing from a clinical stage biotech company to a fully integrated global biopharmaceutical company with cutting-edge global R&D capabilities, a world-class GMP manufacturing facility and commercialization capability. I-Mab has established its global footprint in Shanghai<\/span> (headquarters), Beijing<\/span>, Hangzhou<\/span> and Hong Kong<\/span> in China<\/span>, and Maryland<\/span> and San Diego<\/span> in the United States<\/span>. For more information, please visit\u00a0http:\/\/ir.i-mabbiopharma.com<\/a>\u00a0and follow I-Mab on\u00a0LinkedIn<\/a>,\u00a0Twitter<\/a>\u00a0and\u00a0WeChat<\/a>.<\/p>\n

\n For more information, please contact:<\/b>\n <\/p>\n

\n I-Mab <\/b>\n <\/p>\n

Jielun Zhu, Chief Financial Officer
E-mail:\u00a0jielun.zhu@i-mabbiopharma.com<\/a>\u00a0
Office line: +86 21 6057 8000<\/p>\n

\n Gigi Feng<\/span>, Chief Communications Officer
E-mail:\u00a0gigi.feng@i-mabbiopharma.com<\/a>
Office line: +86 21 6057 5709<\/p>\n

\n Investor Inquiries:<\/b>\n <\/p>\n

\n The Piacente Group, Inc.
<\/i>
\n Emilie Wu<\/span>
\n
E-mail:\u00a0emilie@thepiacentegroup.com<\/a>
Office line: +86 21 6039 8363<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab-301303763.html<\/a><\/p>\n

SOURCE I-Mab<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire SHANGHAI and GAITHERSBURG, Md., June 2, 2021 \/PRNewswire\/ — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors on Monday, June 7 at 8:00 a.m. ET to provide an in-depth clinical data analysis of its U.S. phase 1 study of uliledlimab in combination with atezolizumab (TECENTRIQ\u00ae) in patients with advanced cancers. I-Mab Conference Call Information Investors and analysts are invited to join the conference call on June 7 at 8:00 a.m. ET via Zoom: Meeting URL:\u00a0 https:\/\/zoom.us\/j\/99293081819?pwd=aHJjQ0o4Uk9kUEtzeHI1dngzUGREUT09Meeting ID:\u00a0\u00a0\u00a0\u00a0 992 9308 1819Password:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 942873 About Uliledlimab (TJD5) Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed … <\/p>\n

Continue reading “I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-499973","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nI-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SHANGHAI and GAITHERSBURG, Md., June 2, 2021 \/PRNewswire\/ — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors on Monday, June 7 at 8:00 a.m. ET to provide an in-depth clinical data analysis of its U.S. phase 1 study of uliledlimab in combination with atezolizumab (TECENTRIQ\u00ae) in patients with advanced cancers. I-Mab Conference Call Information Investors and analysts are invited to join the conference call on June 7 at 8:00 a.m. ET via Zoom: Meeting URL:\u00a0 https:\/\/zoom.us\/j\/99293081819?pwd=aHJjQ0o4Uk9kUEtzeHI1dngzUGREUT09Meeting ID:\u00a0\u00a0\u00a0\u00a0 992 9308 1819Password:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 942873 About Uliledlimab (TJD5) Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed … Continue reading "I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-02T12:23:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/821373\/I_MAB_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab\",\"datePublished\":\"2021-06-02T12:23:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\\\/\"},\"wordCount\":432,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/821373\\\/I_MAB_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\\\/\",\"name\":\"I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/821373\\\/I_MAB_Logo.jpg\",\"datePublished\":\"2021-06-02T12:23:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/821373\\\/I_MAB_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/821373\\\/I_MAB_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\/","og_locale":"en_US","og_type":"article","og_title":"I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab - Market Newsdesk","og_description":"PR Newswire SHANGHAI and GAITHERSBURG, Md., June 2, 2021 \/PRNewswire\/ — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors on Monday, June 7 at 8:00 a.m. ET to provide an in-depth clinical data analysis of its U.S. phase 1 study of uliledlimab in combination with atezolizumab (TECENTRIQ\u00ae) in patients with advanced cancers. I-Mab Conference Call Information Investors and analysts are invited to join the conference call on June 7 at 8:00 a.m. ET via Zoom: Meeting URL:\u00a0 https:\/\/zoom.us\/j\/99293081819?pwd=aHJjQ0o4Uk9kUEtzeHI1dngzUGREUT09Meeting ID:\u00a0\u00a0\u00a0\u00a0 992 9308 1819Password:\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 942873 About Uliledlimab (TJD5) Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed … Continue reading \"I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-02T12:23:47+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/821373\/I_MAB_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab","datePublished":"2021-06-02T12:23:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\/"},"wordCount":432,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/821373\/I_MAB_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\/","name":"I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/821373\/I_MAB_Logo.jpg","datePublished":"2021-06-02T12:23:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/821373\/I_MAB_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/821373\/I_MAB_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/i-mab-to-hold-investor-call-to-present-in-depth-phase-1-clinical-data-on-highly-differentiated-cd73-antibody-uliledlimab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=499973"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499973\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=499973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=499973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=499973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}